Direct oral anticoagulants in cancer-associated venous thromboembolism
This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and treatment of venous thromboembolism (VTE) in cancer patients. In accordance with actual guidelines, the duration of anticoagulant therapy for cancer-associated venous thrombosis should be at least 6 months....
Main Authors: | Kirill Lobastov, Ilya Schastlivtsev, Irina Kanzafarova |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Vascular Investigation and Therapy |
Subjects: | |
Online Access: | http://www.vitonline.org/article.asp?issn=2589-9686;year=2020;volume=3;issue=2;spage=46;epage=53;aulast=Lobastov |
Similar Items
-
The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
by: К. V. Lobastov, et al.
Published: (2020-05-01) -
ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01) -
Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
by: Juan J. López-Núñez, et al.
Published: (2019-01-01) -
Fatigue after initiating rivaroxaban for venous thromboembolism
by: Tina Margrethe Karlsvik, et al.
Published: (2020-05-01) -
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis
by: Sobieraj, Diana M., et al.
Published: (2015)